0	6	Mutual	mutual	JJ
7	17	regulation	regulation	NN
18	20	of	of	IN
21	24	the	the	DT
25	40	transcriptional	transcriptional	JJ
41	50	activator	activator	NN
51	59	NF-kappa	NF-kappa	NNP
60	61	B	B	NNP
62	65	and	and	CC
66	69	its	its	PRP$
70	79	inhibitor	inhibitor	NN
79	80	,	,	,
81	82	I	i	NN
83	88	kappa	kappa	NN
89	96	B-alpha	B-alpha	NNP
96	97	.	.	.

99	102	The	the	DT
103	111	NK-kappa	NK-kappa	NNP
112	113	B	B	NNP
114	127	transcription	transcription	NN
128	134	factor	factor	NN
135	142	complex	complex	NN
143	145	is	be	VBZ
146	157	sequestered	sequester	VBN
158	160	in	in	IN
161	164	the	the	DT
165	174	cytoplasm	cytoplasm	NN
175	177	by	by	IN
178	181	the	the	DT
182	192	inhibitory	inhibitory	JJ
193	200	protein	protein	NN
201	202	I	I	NNP
203	208	kappa	kappa	NN
209	216	B-alpha	B-alpha	NNP
217	218	(	(	(
218	223	MAD-3	MAD-3	NNP
223	224	)	)	)
224	225	.	.	.

226	233	Various	various	JJ
234	242	cellular	cellular	JJ
243	250	stimuli	stimulus	NNS
251	258	relieve	relieve	VBP
259	263	this	this	DT
264	274	inhibition	inhibition	NN
275	277	by	by	IN
278	288	mechanisms	mechanism	NNS
289	296	largely	largely	RB
297	304	unknown	unknown	JJ
304	305	,	,	,
306	313	leading	lead	VBG
314	316	to	to	TO
317	325	NF-kappa	NF-kappa	NNP
326	327	B	B	NNP
328	335	nuclear	nuclear	JJ
336	348	localization	localization	NN
349	352	and	and	CC
353	368	transactivation	transactivation	NN
369	371	of	of	IN
372	375	its	its	PRP$
376	382	target	target	NN
383	388	genes	gene	NNS
388	389	.	.	.

390	392	It	it	PRP
393	395	is	be	VBZ
396	408	demonstrated	demonstrate	VBN
409	413	here	here	RB
414	418	with	with	IN
419	424	human	human	JJ
425	426	T	t	NN
427	438	lymphocytes	lymphocyte	NNS
439	442	and	and	CC
443	452	monocytes	monocyte	NNS
453	457	that	that	IN
458	467	different	different	JJ
468	475	stimuli	stimulus	NNS
475	476	,	,	,
477	486	including	include	VBG
487	492	tumor	tumor	NN
493	501	necrosis	necrosis	NN
502	508	factor	factor	NN
509	514	alpha	alpha	NN
515	518	and	and	CC
519	526	phorbol	phorbol	NN
527	539	12-myristate	12-myristate	NN
540	550	13-acetate	13-acetate	NN
550	551	,	,	,
552	557	cause	cause	VBP
558	563	rapid	rapid	JJ
564	575	degradation	degradation	NN
576	578	of	of	IN
579	580	I	i	NN
581	586	kappa	kappa	NN
587	594	B-alpha	B-alpha	NNP
594	595	,	,	,
596	600	with	with	IN
601	612	concomitant	concomitant	JJ
613	623	activation	activation	NN
624	626	of	of	IN
627	635	NF-kappa	NF-kappa	NNP
636	637	B	B	NNP
637	638	,	,	,
639	647	followed	follow	VBN
648	650	by	by	IN
651	652	a	a	DT
653	661	dramatic	dramatic	JJ
662	670	increase	increase	NN
671	673	in	in	IN
674	675	I	i	NN
676	681	kappa	kappa	NN
682	689	B-alpha	B-alpha	NNP
690	694	mRNA	mRNA	NNP
695	698	and	and	CC
699	706	protein	protein	NN
707	716	synthesis	synthesis	NN
716	717	.	.	.

718	730	Transfection	transfection	NN
731	738	studies	study	NNS
739	745	reveal	reveal	VBP
746	750	that	that	IN
751	754	the	the	DT
755	756	I	i	NN
757	762	kappa	kappa	NN
763	770	B-alpha	B-alpha	NNP
771	775	mRNA	mRNA	NNP
776	779	and	and	CC
780	783	the	the	DT
784	791	encoded	encode	VBN
792	799	protein	protein	NN
800	803	are	be	VBP
804	812	potently	potently	RB
813	820	induced	induce	VBN
821	823	by	by	IN
824	832	NF-kappa	NF-kappa	NNP
833	834	B	B	NNP
835	838	and	and	CC
839	841	by	by	IN
842	852	homodimers	homodimer	NNS
853	855	of	of	IN
856	859	p65	p65	NN
860	863	and	and	CC
864	866	of	of	IN
867	872	c-Rel	c-rel	NN
872	873	.	.	.

874	876	We	we	PRP
877	884	propose	propose	VBP
885	886	a	a	DT
887	892	model	model	NN
893	895	in	in	IN
896	901	which	which	WDT
902	910	NF-kappa	NF-kappa	NNP
911	912	B	B	NNP
913	916	and	and	CC
917	918	I	i	NN
919	924	kappa	kappa	NN
925	932	B-alpha	B-alpha	NNP
933	941	mutually	mutually	RB
942	950	regulate	regulate	VBP
951	955	each	each	DT
956	961	other	other	JJ
962	964	in	in	IN
965	966	a	a	DT
967	972	cycle	cycle	NN
972	973	:	:	:
974	984	saturating	saturating	JJ
985	992	amounts	amount	NNS
993	995	of	of	IN
996	999	the	the	DT
1000	1010	inhibitory	inhibitory	JJ
1011	1012	I	i	NN
1013	1018	kappa	kappa	NN
1019	1026	B-alpha	B-alpha	NNP
1027	1034	protein	protein	NN
1035	1038	are	be	VBP
1039	1048	destroyed	destroy	VBN
1049	1053	upon	upon	IN
1054	1065	stimulation	stimulation	NN
1065	1066	,	,	,
1067	1075	allowing	allow	VBG
1076	1081	rapid	rapid	JJ
1082	1092	activation	activation	NN
1093	1095	of	of	IN
1096	1104	NF-kappa	NF-kappa	NNP
1105	1107	B.	B.	NNP
1108	1120	Subsequently	Subsequently	NNP
1120	1121	,	,	,
1122	1123	I	i	NN
1124	1129	kappa	kappa	NN
1130	1137	B-alpha	B-alpha	NNP
1138	1142	mRNA	mRNA	NNP
1143	1146	and	and	CC
1147	1154	protein	protein	NN
1155	1161	levels	level	NNS
1162	1165	are	be	VBP
1166	1173	quickly	quickly	RB
1174	1181	induced	induce	VBN
1182	1184	by	by	IN
1185	1188	the	the	DT
1189	1198	activated	activate	VBN
1199	1207	NF-kappa	NF-kappa	NNP
1208	1210	B.	B.	NNP
1211	1215	This	this	DT
1216	1226	resurgence	resurgence	NN
1227	1229	of	of	IN
1230	1231	I	i	NN
1232	1237	kappa	kappa	NN
1238	1245	B-alpha	B-alpha	NNP
1246	1253	protein	protein	NN
1254	1258	acts	act	VBZ
1259	1261	to	to	TO
1262	1269	restore	restore	VB
1270	1272	an	an	DT
1273	1284	equilibrium	equilibrium	NN
1285	1287	in	in	IN
1288	1293	which	which	WDT
1294	1302	NF-kappa	NF-kappa	NNP
1303	1304	B	B	NNP
1305	1307	is	be	VBZ
1308	1313	again	again	RB
1314	1323	inhibited	inhibit	VBN
1323	1324	.	.	.